[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteoarthritis-hand\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteoarthritis-hand":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,70,91,116,139,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100609655","phase-4-radiotherapy-compared-to-corticosteroid-injection-for-treatment-of-hand-osteoarthritis-100609655",false,"NCT07217405","Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis","Low-Dose Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis","Inclusion Criteria:\n\n* Patient at Mayo Clinic, Rochester, MN\n* Age 50 years or older\n* Mild, moderate, or severe hand OA (Kellgren and Lawrence classification grade 2, 3, or 4) on hand radiographs within the last 24 months\n* Hand OA pain with a minimum VAS score relating to hand pain of ≥40 (on a 100-point scale) when using the affected hand\n* Ability to complete study questionnaires\n\nExclusion Criteria:\n\n* History of previous surgery to the affected hand(s)\n* Autoimmune joint disease such as rheumatoid arthritis or psoriatic arthritis\n* Active confounding hand condition such as stenosing tenosynovitis or Dupuytren's contracture\n* Recent injury (within last 1 month) to the affected hand causing current pain\n* History of crystalline arthritis (gout or pseudogout) flare in the affected hand(s)\n* Active use of opioid pain medication(s) or oral steroids within the last 3 months\n* Fibromyalgia or central sensitization syndrome\n* Hand CSI or other hand injection within the past 3 months\n* History of hand LDRT within the past 3 months\n* Poorly controlled diabetes (HbA1c \\> 10%)\n* Active infection\n* Current pregnancy","ALL","50 Years",{"count":19,"type":20},165,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The purpose of this research is to compare low-dose radiotherapy to corticosteroid injection for treatment of hand\u002Fwrist osteoarthritis.",[26,27],"Osteoarthritis Hand","Osteoarthritis Wrist","RECRUITING","2026-04-21",{"date":31,"type":32},"2026-04-24","ACTUAL",{"date":34,"type":32},"2025-12-19",{"date":36,"type":20},"2027-10-01",{"name":38,"class":39},"Mayo Clinic","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100518724","phase-2-use-of-a-treated-devitalized-and-sterile-umbilical-cord-amniotic-membrane-in-the-treatment-of-pip-joint-osteoarthritis-100518724","NCT06034262","Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of PIP Joint Osteoarthritis","Evaluation of the Treatment of Symptomatic Proximal InterPhalangeal (PIP) Joint Osteoarthritis With a Treated, Devitalized and Sterile Amniotic Membrane of Umbilical Cord Placed in Joint Interposition","Inclusion Criteria:\n\n* Male or female; age between 18 and 75 years.\n* Patient with symptomatic PIPJ OA.\n* Patient treated medically for functional signs for more than 3 months, without improvement, justifying a surgical intervention.\n* Patient with a QuickDash score \\> 33 points (converted to 50%).\n* Patient with pain, at rest, in the PIPJ ≥ 4\u002F10 on a VAS.\n* Patient who received the study information and provided consent.\n* Member or beneficiary of a national health insurance plan.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman; woman without effective contraception.\n* Patient with signs of neuropathy with functional disorders such as hyperesthesia.\n* Patient with uncontrolled epilepsy or neuropathy that contraindicates locoregional anesthesia.\n* Person confined by a judicial or administrative decision.\n* Adult subjected to legal protection measures or unable to provide his\u002Fher consent.","18 Years","75 Years",{"count":51,"type":20},14,[53],"PHASE2","The aim of this open, prospective, multicenter trial is to evaluate the use of a sterile, devitalized, processed umbilical cord amniotic membrane implant placed in joint interposition in the treatment of PIP joint osteoarthritis.",[26],[57,58],"Proximal InterPhalangeal Joint (PIPJ)","OsteoArthritis (OA)","2025-09-24",{"date":61,"type":32},"2025-09-26",{"date":63,"type":32},"2024-10-07",{"date":65,"type":20},"2026-01",{"name":67,"class":68},"TBF Genie Tissulaire","INDUSTRY",3,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100519037","phase-2-use-of-a-treated-devitalized-and-sterile-umbilical-cord-amniotic-membrane-in-the-treatment-of-stt-osteoarthritis-100519037","NCT06038331","Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis","Evaluation of the Treatment of Symptomatic Scaphotrapeziotrapezoidal (STT) Osteoarthritis With a Treated, Devitalized and Sterile Amniotic Membrane of Umbilical Cord Placed in Joint Interposition","Inclusion Criteria:\n\n* Male or female; age between 18 and 75 years.\n* Patient with symptomatic STT OA.\n* Patient treated medically for functional signs for more than 3 months, without improvement, justifying a surgical intervention.\n* Patient with a QuickDash score \\> 33 points (converted to 50%).\n* Patient with wrist pain in front of the STT joint at rest = or \\> 4\u002F10 on VAS.\n* Patient who received the study information and provided consent.\n* Member or beneficiary of a national health insurance plan.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman; woman without effective contraception.\n* Patient with functional rhizarthrosis that has not been stabilized or treated medically or surgically.\n* Patient with signs of neuropathy with functional disorders such as hyperesthesia.\n* Patient with uncontrolled epilepsy or neuropathy that contraindicates locoregional anesthesia.\n* Person confined by a judicial or administrative decision.\n* Adult subjected to legal protection measures or unable to provide his\u002Fher consent.",{"count":51,"type":20},[53],"The aim of this open, prospective, multicenter trial is to evaluate the use of a sterile, devitalized, processed umbilical cord amniotic membrane implant placed in joint interposition in the treatment of STT osteoarthritis.",[26],[82],"ScaphoTrapezioTrapezoid OsteoArthritis (STT OA)",{"date":84,"type":32},"2025-09-30",{"date":86,"type":32},"2024-05-28",{"date":88,"type":20},"2026-12",{"name":67,"class":68},4,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":40},"100468366","efficacy-of-surgical-joint-denervation-in-painful-digital-osteoarthritis-100468366","NCT05378841","Efficacy of Surgical Joint Denervation in Painful Digital Osteoarthritis","DECAD","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients with symptomatic digital osteoarthritis according to the criteria of the American College of Rheumatology\n* 1 painful PIP joint (Analog digital scale ≥ 4\u002F10) for more than 3 months\n* having failed the usual medical treatment for a minimum of 3 months (level 1 analgesics, NSAIDs, infiltrations)\n* Signature of informed consent\n* patient affiliated to a social security scheme\n* knowing how to read French (for the questionnaires)\n\nExclusion Criteria:\n\n* digital osteoarthritis secondary to other known causes (eg gout, reactive arthritis, RA, psoriatic arthritis, spondyloarthropathies, septic arthritis)\n* anesthetic contraindications to surgery or to performing an MRI\n* Existence of a pain syndrome in the upper limbs, which would interfere with the assessment of AD.\n* Fibromyalgia\n* Use of oral, intramuscular or intra-articular or intravenous corticosteroids, immunosuppressants (methotrexate, sulfasalazine, leflunomide, biomedicines), hyaluronic acid infiltration in the finger joints in the previous month\n* Introduction of a new treatment for osteoarthritis of the hand in the previous month, including physiotherapy and fitting of a new finger orthosis.\n* History of denervation of the proximal interphalangeal joint (PIP)\n* Patient under legal protection (guardianship or curatorship) and patient deprived of liberty\n* Patient under AME\n* Participation in another interventional research involving the human person or period of exclusion at the end of a previous research involving the human person.",{"count":99,"type":20},19,[101],"NA","Digital osteoarthritis is the second localization of symptomatic osteoarthritis, after the knee. Its cardinal symptoms are particularly intense pain and functional impairment in the case of the erosive form. There is currently no etiological treatment for osteoarthritis. Symptomatic treatments have a modest efficacy, which justifies the search for new treatments. The surgical options are arthrodesis or prosthesis, invasive techniques potentially sources of complications, and finally proposed infrequently given the prevalence of digital osteoarthritis.\n\nDECAD is a prospective phase II trial aimed at evaluating the efficacy of surgical joint denervation in painful digital osteoarthritis.",[26],[105,106],"Digital osteoarthritis","Surgical joint dernervation","2025-07-09",{"date":109,"type":32},"2025-07-14",{"date":111,"type":32},"2023-06-05",{"date":113,"type":20},"2026-06-15",{"name":115,"class":39},"Assistance Publique - Hôpitaux de Paris",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":21,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":90},"100550272","phase-4-capsaicin-in-digital-osteoarthritis-versus-control-100550272","NCT06444919","Capsaicin in Digital Osteoarthritis Versus Control","Capsaicin in Digital Osteoarthritis Versus Control : a Randomized Study","CADOR","Inclusion Criteria:\n\n* Diagnosis of digital osteoarthritis fulfilling the American College of Rheumatology criteria;\n* Presence of finger pain of ≥ 40 mm on a visual analogue scale (VAS);\n* Presence of finger pain with a neuropathic pain component (DN4 score ≥ 4\u002F10)\n* Inadequate response, adverse reactions, and\u002For contraindications to conventional analgesics and NSAIDs;\n\nExclusion Criteria:\n\n* Patient with isolated rhizarthrosis;\n* Patient with other joint disease affecting the fingers (gout, chondrocalcinosis, RA, spondyloarthritis, psoriatic arthritis);\n* Patient with upper extremity pain syndrome that may interfere with the assessment of finger pain;\n* Patient with another pathology responsible for neuropathic hand pain (carpal tunnel syndrome, diabetic neuropathy, Guyon's tunnel syndrome, cervicobrachial neuralgia, brachial plexitis);\n* Patient with skin lesions on the fingers (psoriasis, wounds, chronic ulcers, eczema, shingles, dermatitis);\n* Patient with poorly controlled high blood pressure;\n* Patient with hypersensitivity to capsaicin;\n* Patient who had 8% capsaicin patch use in the year prior to the study;\n* Patient who has received intramuscular, intra-articular or intravenous corticosteroid therapy, another disease-modifying anti-rheumatic therapy (methotrexate, salazopyrine) or an intra-articular injection into the joints of the fingers within the previous 3 months;\n* Patient wearing wrist or finger orthoses in the previous month;\n* Patient with fibromyalgia;",{"count":125,"type":20},120,[23],"The objective of this multicentric, randomized controlled double-blind clinical trial is to demonstrate the efficacy of transdermal application of capsaicin in patients with painful digital osteoarthritis with a neuropathic pain component.\n\nParticipants will receive either a transdermal patch of capsaicin 179 mg (8%) or the control treatment (capsaicin 0.04%).\n\nResearchers will compare the intensity of pain in the fingers at day 60 in the capsaicin 8% group versus capsaicin 0.04% (control arm)",[26,129],"Neuropathic Pain","2025-03-12",{"date":132,"type":32},"2025-03-13",{"date":134,"type":20},"2025-03-07",{"date":136,"type":20},"2028-01-01",{"name":138,"class":39},"University Hospital, Clermont-Ferrand",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":40},"100510230","cardiovascular-risk-in-digital-osteoarthritis-100510230","NCT05923736","Cardiovascular Risk in Digital Osteoarthritis","Assessment of Cardiovascular Risk in Digital Osteoarthritis: A Case-control Study.","RICARDI","Inclusion Criteria:\n\nFor all subjects:\n\n* Adult male or female subject\n* Able to give informed consent to participate in research\n* Affiliated with a Social Security plan\n\nFor the digital osteoarthritis group:\n\n* Consultant in Rheumatology at Clermont-Ferrand University Hospital\n* Affected by digital osteoarthritis meeting ACR diagnostic criteria with radiographic signs of osteoarthritis validated by a radiologist.\n\nFor the control group :\n\n* Rheumatology consultant at the Clermont-Ferrand University Hospital or hospitalized in this department for a non-arthritic, non-rheumatic pathology.\n* Patients with spinal disc pathology (lumbago, radiculalgia due to disco-radicular conflict) or non-severe osteoporosis, i.e. with a densitometric T score between -2.5 and -3 DS.\n\nExclusion Criteria:\n\nFor all topics :\n\n* Refusal to participate\n* Pregnant women, nursing mothers\n* Subjects under guardianship or curatorship, deprived of liberty, or under court protection\n\nFor the digital osteoarthritis group:\n\n\\- Existence of diagnostic arguments for another inflammatory rheumatism (rheumatoid arthritis, spondylarthritis, psoriatic arthritis, lupus, gout, chondrocalcinosis...) or another arthrosic localization (gonarthrosis, coxarthrosis, discarthrosis) symptomatic at the time of inclusion or affecting daily activities.\n\nFor the control group :\n\n* Existence of chronic inflammatory rheumatism (rheumatoid arthritis, spondylitis, psoriatic arthritis, lupus, gout, chondrocalcinosis...)\n* Existence of digital osteoarthritis\n* Existence of another painful arthritic site (knee, hip, rachi) Existence of finger pain, whatever the etiology.",{"count":148,"type":20},100,[101],"The goal of this cross-sectional case control study is to investigate the cardiovascular risk in digital osteoarthritis. This study aims to compare the cardiovascular risk between group of patients with digital osteoarthritis and control group of patients with non-osteoarthritis disease paired by measurement of carotid intima-media thickness. All participants will undergo an ultrasound scan to measure carotid intima media thickness, a clinical assessment with the rheumatologist and a cardiovascular risk assessment.",[26,152,153,154],"Lumbago","Osteoporosis","Radiculopathy Lumbar","2024-04-02",{"date":157,"type":32},"2024-04-03",{"date":159,"type":32},"2023-10-04",{"date":161,"type":20},"2026-10-04",{"name":138,"class":39},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":173,"phases":4,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":40},"100476450","capflex-pip-implant-rsa-100476450","NCT05484089","CapFlex PIP Implant RSA","Migration of the CapFlex-PIP Implant System for Proximal Interphalangeal Joint Arthroplasty: a 10 Year Follow up RSA Study","Capflex RSA","Inclusion Criteria:\n\n* Indication for PIP joint arthroplasty as described in the manufacturer's guideline, namely as a result of:\n\n  * Painful osteoarthritis\n  * Instable communitive intra-articular PIP fractures\n* Age \\> 18 years\n* Patient is able to speak and write Dutch\n* Patient is willing to participate\n* Patient is able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Inflammatory arthritis with significant bone loss\n* Insufficient bone quality to provide adequate stability\n* Known or suspected sensitivity or allergy to one or more of the implant materials\n* Revision surgery\n* Significant collateral instability\n* Pregnancy or breastfeeding",{"count":172,"type":20},36,"OBSERVATIONAL","Rationale: Patients with osteoarthrtis (OA) of the proximal interphalangeal (PIP) joint are commonly treated with joint arthroplasty. The CapFlex PIP implant is a modular surface replacing implant, which has good short-term functional results with a relatively low complication rate. To reduce implant failure and to increase long-term survival, it is important to expand knowledge about fixation and loosening patterns. By using model-based roentgen stereogrammaetric analysis (mRSA), the migration pattern of the implant over time can be calculated.\n\nObjective: The primary objective is to assess the fixation and migration patterns of the CapFlex PIP implant system (produced and developed by several companies of KLS Martin Group) in vivo, using mRSA, over 10 years. Secondary objectives are to analyse survival, clinical scores and radiographic aspects of the CapFlex PIP implant system.\n\nStudy design: A prospective cohort study with 10 years follow-up, in which 36 patients will be enrolled. Patients will be evaluated preoperatively, at 6 weeks, 6 months, 1 year, 2 years 5 years and 10 years.\n\nStudy population: Patients 18 years or older who require a proximal interphalangeal joint arthroplasty as a result of osteoarthritis of a proximal interphalangeal joint.\n\nMain study parameters\u002Fendpoints: The main study parameters are the migration of the CapFlex PIP implant system of the distal as well as the proximal component (presented in x-, y- and z-direction). Secondary study parameters are the survival of the CapFlex PIP implant system, clinical scores and radiographic aspects.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients participating in the study will have the same risks when not participating in the study. Patients are asked to spend time to fill in the questionnaires and to have 3 extra visits to the hospital, next to the standard visits. Patients will have more follow up visits and will be followed using RSA analysis, which has as advantage that possible complications might be noticed earlier compared to normal follow up.",[26],[177,178],"RSA","Osteoarthritis","2023-10-27",{"date":181,"type":32},"2023-10-31",{"date":183,"type":32},"2023-10-25",{"date":185,"type":20},"2035-10",{"name":187,"class":39},"Reinier Haga Orthopedisch Centrum"]